Clinical trials
Participants With Advanced Solid Tumor Malignancies clinical trials
Below are recruiting participants with advanced solid tumor malignancies clinical trials, each written for real people, not researchers. We’re tracking 776 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07477743RecruitingPhase 1
Study of a new drug combo for advanced solid tumors
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
BeijingAges 18–75 - NCT06782425RecruitingPhase 1
Cell therapy for advanced stomach cancer with Claudin18.2 protein
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
Anyang, HenanAges 18–75 - NCT07480733RecruitingPhase 2
Study of two drugs for advanced solid tumors
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06782334RecruitingPhase 1/Phase 2
AMT-116 for advanced solid tumors
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT07467629RecruitingPhase 1
Study of QLS5212 for people with advanced solid tumors
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
TaiyuanAges 18 years+ - NCT07469774RecruitingPhase 1/Phase 2
BC3195 plus Keytruda for advanced solid tumors
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT07469982RecruitingPhase 1
Study of SY-9453 for advanced solid tumors
This trial tests an experimental pill called SY-9453 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if it is safe and how the body processes it. It may be an option if you have tried standard treatments without success.
ShanghaiAges 18 years+ - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05341557RecruitingPhase 1
First-in-human drug study for advanced cancers and lymphoma
This Phase 1 trial tests BPI-371153, a new treatment, in people with advanced solid tumors or relapsed or refractory lymphoma whose cancer has returned or progressed after standard care. The goal is to find a safe dose and learn whether it can shrink tumors or help control disease.
Chaoyang, Beijing MunicipalityAges 18 years+ - NCT05789602RecruitingPhase 1
Study drug for advanced solid tumors in adults
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07455617RecruitingPhase 1
Vaccine for KRAS-mutated advanced solid tumors
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
ShanghaiAges 18 years+ - NCT07459998RecruitingPhase 1/Phase 2
SKB103 study for advanced solid tumors
This trial tests a new drug called SKB103 for people with advanced solid tumors that have not responded to standard treatments or who cannot tolerate them. The study aims to see if SKB103 is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT07459283RecruitingEarly Phase 1
Study of 177Lu-INN805 for advanced solid tumors
This trial tests a new treatment called 177Lu-INN805 for people with advanced solid tumors that have not responded to standard therapies. It aims to see if the drug is safe, where it goes in the body, and whether it can shrink tumors.
Wuxi, JiangsuAges 18–75 - NCT07455734RecruitingPhase 1/Phase 2
Testing BNT3214 for advanced solid tumors
This trial tests an experimental drug, BNT3214, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if BNT3214 is safe and helps shrink tumors.
ClaytonAges 18 years+ - NCT07456046RecruitingPhase 1
Study of D3S-003 for advanced solid tumors with KRAS G12D mutation
This trial tests a new medicine called D3S-003 in people whose cancer has a specific change (mutation) known as KRAS G12D. The medicine aims to target and attack cancer cells with this mutation. It may be an option if standard treatments have stopped working or are not available.
New Haven, ConnecticutAges 18 years+ - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Orange, CaliforniaAges 18 years+ - NCT06718946RecruitingEarly Phase 1
IV IDOV-SAFE for advanced solid tumors: safety and effect study
This trial tests a new drug called IDOV-SAFE given through a vein. It is for people with advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug is safe and if it can help shrink tumors.
ShanghaiAges 18–75 - NCT07433283RecruitingPhase 1/Phase 2
Iron nanoparticle injection for advanced solid tumors
This trial tests a new treatment for advanced solid tumors that uses tiny iron particles guided by carbon nanoparticles, injected directly into the tumor. It may be an option if standard treatments have stopped working or aren't available, and you have a tumor that can be safely injected.
Beijing, Beijing MunicipalityAges 18–80 - NCT07431073RecruitingPhase 2
Immunotherapy master trial for advanced cancers
This trial tests different immunotherapy treatments for people with advanced cancer that has spread or cannot be removed by surgery. It aims to find out which treatments work best by studying your tumor and blood samples over time.
VillejuifAges 12 years+ - NCT06464055RecruitingPhase 1/Phase 2
A study of GQ1010 for advanced solid tumors
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
BeijingAges 18 years+ - NCT07417189RecruitingPhase 1/Phase 2
Study of ABSK141 for advanced solid tumors with KRAS G12D mutation
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
ShanghaiAges 18 years+ - NCT06820424RecruitingEarly Phase 1
CDH17-targeted CAR-T cells for advanced solid tumors
This trial tests a new type of immunotherapy that uses your own modified immune cells (CAR-T cells) to find and attack cancer cells that carry a specific marker called CDH17. It is for adults with advanced solid tumors that have CDH17 and who have run out of standard treatment options.
Kunming, YunnanAges 18–75
Hear when a new Participants With Advanced Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participants with advanced solid tumor malignancies?
- Yes. Clin2 currently lists 776 recruiting participants with advanced solid tumor malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participants with advanced solid tumor malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participants with advanced solid tumor malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.